In the training set, univariate analysis of clinical characteristics that might be associated with platinum-resistance in patients with epithelial ovarian cancer showed significant differences between platinum-sensitive and platinum-resistant patients in age, lymph node metastasis, vascular cancer thrombus, ascites cancer cells, neoadjuvant chemotherapy, and tumor marker HE4. This evidence concerns the gene WFDC2 and metastatic malignant neoplasm in the lymph nodes.